Immutep Reports Promising Phase I Data for First-in-Class Autoimmune Antibody IMP761

An announcement from Immutep Ltd ( (AU:IMM) ) is now available.

Immutep reported encouraging interim data from a first-in-human Phase I trial of IMP761, its first-in-class LAG-3 agonist antibody candidate for autoimmune diseases, showing that single-ascending doses at 2.5 and 7 mg/kg were well tolerated with only mild treatment-related effects. The study also demonstrated a clear dose-dependent and long-lasting immunosuppressive effect, with substantial reductions in T cell activity against a strong foreign antigen, reinforcing proof-of-concept that IMP761 may selectively silence dysregulated T cells at inflamed disease sites and potentially offer a more targeted treatment option for major autoimmune indications such as rheumatoid arthritis, Type 1 diabetes and multiple sclerosis; the trial will continue as planned, with further data expected in the first half of 2026, underscoring Immutep’s strategic positioning in the emerging LAG-3 autoimmune therapy market.

The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company specialising in novel immunotherapies for cancer and autoimmune diseases. A pioneer in LAG-3 (lymphocyte activation gene-3) biology, the company develops a diversified portfolio of drug candidates that modulate the immune system by either stimulating or suppressing immune responses, targeting large and growing markets in oncology and autoimmune conditions.

YTD Price Performance: 8.22%

Average Trading Volume: 3,247,204

Technical Sentiment Signal: Buy

Current Market Cap: A$582.1M

For an in-depth examination of IMM stock, go to TipRanks’ Overview page.